Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Drops By 44.9%

TransCode Therapeutics, Inc. (NASDAQ:RNAZGet Rating) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 24,700 shares, a decrease of 44.9% from the March 31st total of 44,800 shares. Based on an average daily trading volume, of 17,900 shares, the short-interest ratio is presently 1.4 days. Currently, 0.3% of the shares of the stock are short sold.

Several hedge funds and other institutional investors have recently modified their holdings of RNAZ. K.J. Harrison & Partners Inc acquired a new stake in TransCode Therapeutics during the fourth quarter worth about $41,000. Geode Capital Management LLC acquired a new stake in TransCode Therapeutics during the third quarter worth about $50,000. National Asset Management Inc. acquired a new stake in TransCode Therapeutics during the third quarter worth about $75,000. Two Sigma Securities LLC acquired a new stake in TransCode Therapeutics during the third quarter worth about $100,000. Finally, ACT Capital L.L.C. acquired a new stake in TransCode Therapeutics during the third quarter worth about $150,000. Institutional investors and hedge funds own 19.49% of the company’s stock.

Shares of NASDAQ RNAZ opened at $2.73 on Friday. The firm has a 50-day simple moving average of $2.56 and a 200-day simple moving average of $2.61. TransCode Therapeutics has a 52 week low of $1.95 and a 52 week high of $7.00.

About TransCode Therapeutics (Get Rating)

TransCode Therapeutics, Inc, a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers.

Read More

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.